HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sleep patterns of Down's syndrome children: effects of butoctamide hydrogen succinate (BAHS) administration.

Abstract
Several investigators have described the altered sleep patterns in Down's syndrome subjects. The most relevant findings have been a reduction in percentage of REM sleep, a prolonged latency to the first REM episode, an increase in undifferentiated sleep, and a reduced ratio of the oculomotor frequencies. Because it is of interest to identify new drugs able to increase the percentage of REM sleep in mentally retarded subjects, we studied the effects of butoctamide hydrogen succinate (BAHS) on nocturnal sleep in eight young institutionalized Down's syndrome subjects. BAHS produced a significant increase in the percentage of REM sleep as well as a decrease in undifferentiated sleep and latency to the first REM.
AuthorsJ C Grubar, G L Gigli, R M Colognola, R Ferri, S A Musumeci, P Bergonzi
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 90 Issue 1 Pg. 119-22 ( 1986) ISSN: 0033-3158 [Print] Germany
PMID2945221 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amides
  • Hydroxybutyrates
  • butoctamide succinate
Topics
  • Amides
  • Child
  • Down Syndrome (physiopathology)
  • Electroencephalography
  • Humans
  • Hydroxybutyrates (adverse effects, pharmacology)
  • Male
  • Sleep (drug effects)
  • Sleep, REM (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: